Madrigal Pharmaceuticals: Rezdiffra First-Mover Advantage Gains Traction (Upgrade)
Madrigal Pharmaceuticals' Rezdiffra had a strong launch with $103.3M in Q4 sales and solid liquidity. See why I have a ...
Madrigal Pharmaceuticals Inc (MDGL) Q4 2024 Earnings Call Highlights: Strong Sales Growth and ...
Madrigal Pharmaceuticals Inc (MDGL) reports robust financial performance with significant milestones in Rezdiffra's launch ...
Madrigal Pharmaceuticals price target raised to $239 from $154 at BofA
BofA raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $239 from $154 and keeps an Underperform rating on ...
Madrigal Pharmaceuticals (NASDAQ:MDGL) Hits New 1-Year High on Better-Than-Expected Earnings
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) reached a new 52-week high on Thursday after the company announced better than expected quarterly earnings. The stock traded as high as ...
JMP Securities Reaffirms Their Buy Rating on Madrigal Pharmaceuticals (MDGL)
JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report) today and set a price ...
Decoding Madrigal Pharmaceuticals's Options Activity: What's the Big Picture?
Benzinga's options scanner spotted 9 options trades for Madrigal Pharmaceuticals. This is not a typical pattern. The sentiment among these major traders is split, with 44% bullish and 44% bearish.
Madrigal Pharmaceuticals Q4 Earnings Review: Strong Quarter, Even Stronger Outlook
Madrigal Pharmaceuticals, Inc.'s Rezdiffra, the first approved drug for MASH, showed strong sales growth, with Q4 net sales ...
Madrigal price target raised to $405 from $400 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $405 from $400 and keeps a Buy rating on the shares ...
WTOP News2d
Madrigal: Q4 Earnings Snapshot
WEST CONSHOHOCKEN, Pa. (AP) — WEST CONSHOHOCKEN, Pa. (AP) — Madrigal Pharmaceuticals Inc. (MDGL) on Wednesday reported a loss of $59.4 million in its fourth quarter. The West Conshohocken ...
Madrigal Pharma stock jumps on positive trial results and revenue beat
Investing.com -- Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ: NASDAQ: MDGL) rose 17% following the announcement of their fourth-quarter and full-year 2024 financial results, which included a ...
ETF Daily News5d
State of New Jersey Common Pension Fund D Reduces Stock Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
State of New Jersey Common Pension Fund D lessened its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 13.8% during the fourth quarter, according to the company ...